Gilead Sciences announced plans to invest $5.1 billion to increase its stake in Dutch biotech firm Galapagos, with an upfront payment of $3.95 billion and an investment of $1.1 billion to be made by Gilead, while the partners will develop and market treatments for a decade. Galapagos needs to ask for shareholder approval prior to allowing Gilead to raise its ownership stake further.
Gilead to invest $5.1B in investment deal with Belgium-based Galapagos
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.